Clinical Significance of Persistent Tumor in Bone Marrow during Treatment of High-risk Neuroblastoma
Open Access
- 1 January 2015
- journal article
- Published by XMLink in Journal of Korean Medical Science
- Vol. 30 (8) , 1062-1067
Abstract
Choi YB, et al. J Korean Med Sci. 2015 Aug;30(8):1062-1067. https://doi.org/10.3346/jkms.2015.30.8.1062Keywords
Funding Information
- Ministry of Health and Welfare (HI13C1521)
This publication has 13 references indexed in Scilit:
- Morphologic Analysis of Pulmonary Neuroendocrine TumorsThe Korean Journal of Pathology, 2013
- The degree of tumor volume reduction during the early phase of induction chemotherapy is an independent prognostic factor in patients with high‐risk neuroblastomaCancer, 2012
- Minimal Residual Disease is a Prognostic Marker for Neuroblastoma With Bone Marrow InfiltrationAmerican Journal of Clinical Oncology, 2012
- Tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma: Results of SMC NB-2004 studyBone Marrow Transplantation, 2012
- Clinicopathological Analysis of 21 Thymic Neuroendocrine TumorsThe Korean Journal of Pathology, 2012
- Measurement of tyrosine hydroxylase transcripts in bone marrow using biopsied tissue instead of aspirates for neuroblastomaPediatric Blood & Cancer, 2010
- Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastomaBone Marrow Transplantation, 2007
- Revision of the International Neuroblastoma Pathology ClassificationCancer, 2003
- Disease Outcome May Be Predicted by Molecular Detection of Minimal Residual Disease in Bone Marrow in Advanced Neuroblastoma: A Pilot StudyJournal of Pediatric Hematology/Oncology, 2001
- Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastomaMedical and Pediatric Oncology, 2001